{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:00:07Z","timestamp":1794031207822,"version":"4.8.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00277-023-05167-9","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T01:02:41Z","timestamp":1678842161000},"page":"1215-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1438-3623","authenticated-orcid":false,"given":"Hidehiro","family":"Itonaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Ara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"issue":"3","key":"5167_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1056\/NEJM200101183440303","volume":"344","author":"W Bensinger","year":"2001","unstructured":"Bensinger W, Martin P, Storer B, Clift R, Forman S, Negrin R et al (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344(3):175\u2013181","journal-title":"N Engl J Med"},{"issue":"9211","key":"5167_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(00)02090-0","volume":"355","author":"R Powles","year":"2000","unstructured":"Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al (2000) Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 355(9211):1231\u20131237","journal-title":"Lancet"},{"issue":"11","key":"5167_CR3","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/sj.bmt.1702422","volume":"25","author":"D Heldal","year":"2000","unstructured":"Heldal D, Tj\u00f8nnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R et al (2000) A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25(11):1129\u20131136","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5167_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.2000.18.3.537","volume":"18","author":"D Blaise","year":"2000","unstructured":"Blaise D, Kuentz M, Fortanier C, Bourhis J, Milpied N, Sutton L et al (2000) Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle. J Clin Oncol 18(3):537\u2013546","journal-title":"J Clin Oncol"},{"issue":"5","key":"5167_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/blood-2002-01-0048","volume":"100","author":"S Couban","year":"2002","unstructured":"Couban S, Simpson D, Barnett M, Bredeson C, Hubesch L, Howson-Jan K et al (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100(5):1525\u20131531","journal-title":"Blood"},{"issue":"12","key":"5167_CR6","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1182\/blood.V98.12.3186","volume":"98","author":"J Morton","year":"2001","unstructured":"Morton J, Hutchins C, Durrant S (2001) Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 98(12):3186\u20133191","journal-title":"Blood"},{"issue":"12","key":"5167_CR7","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.bmt.1701510","volume":"22","author":"A Vigorito","year":"1998","unstructured":"Vigorito A, Azevedo W, Marques J, Azevedo A, Eid K, Aranha F et al (1998) A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 22(12):1145\u20131151","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"5167_CR8","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","volume":"23","author":"Stem Cell Trialists' Collaborative Group","year":"2005","unstructured":"Stem Cell Trialists' Collaborative Group (2005) Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 23(22):5074\u20135087","journal-title":"J Clin Oncol"},{"issue":"19","key":"5167_CR9","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1056\/NEJMra0902908","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361(19):1872\u20131885","journal-title":"N Engl J Med"},{"issue":"7","key":"5167_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"J Khoury","year":"2022","unstructured":"Khoury J, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"11","key":"5167_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"D Arber","year":"2022","unstructured":"Arber D, Orazi A, Hasserjian R et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"2","key":"5167_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2016.266","volume":"52","author":"M Robin","year":"2017","unstructured":"Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G et al (2017) Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant 52(2):209\u2013215","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5167_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","volume":"28","author":"Z Lim","year":"2009","unstructured":"Lim Z, Brand R, Martino R, Biezen A, Finke J, Bacigalupo A et al (2009) Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28(3):405\u2013411","journal-title":"J Clin Oncol"},{"issue":"21","key":"5167_CR14","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","volume":"31","author":"J Koreth","year":"2013","unstructured":"Koreth J, Pidala J, Perez W, Deeg H, Garcia-Manero G, Malcovati L et al (2013) Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 31(21):2662\u20132670","journal-title":"J Clin Oncol"},{"key":"5167_CR15","doi-asserted-by":"publisher","unstructured":"DeFilipp Z, Ciurea SO, Cutler C et al (2022) Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the American Society for Transplantation and Cellular Therapy Committee on practice guidelines. Transplant Cell Ther. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.014","DOI":"10.1016\/j.jtct.2022.11.014"},{"issue":"3","key":"5167_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41408-019-0192-x","volume":"9","author":"K Ishiyama","year":"2019","unstructured":"Ishiyama K, Aoki J, Itonaga H et al (2019) Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for hematopoietic cell transplantation. Blood Cancer J 9(3):31","journal-title":"Blood Cancer J"},{"issue":"6","key":"5167_CR17","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00277-019-03653-7","volume":"98","author":"H Itonaga","year":"2019","unstructured":"Itonaga H, Ishiyama K, Aoki K et al (2019) Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. Ann Hematol 98(6):1367\u20131381","journal-title":"Ann Hematol"},{"key":"5167_CR18","doi-asserted-by":"publisher","unstructured":"Konuma T, Itonaga H, Ishiyama K et al (2023) Progress in survival following three decades of allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a real-world registry study in Japan. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.26839","DOI":"10.1002\/ajh.26839"},{"key":"5167_CR19","volume-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"R Phelan","year":"2020","unstructured":"Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020. https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx."},{"issue":"9","key":"5167_CR20","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1182\/blood.V97.9.2541","volume":"97","author":"S Rowley","year":"2001","unstructured":"Rowley S, Donaldson G, Lilleby K, Bensinger W, Appelbaum F (2001) Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 97(9):2541\u20132548","journal-title":"Blood"},{"issue":"10","key":"5167_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0301-472X(03)00195-4","volume":"31","author":"J Cornelissen","year":"2003","unstructured":"Cornelissen J, Holt B, Petersen E, Vindelov L, Russel C, H\u00f6glund M et al (2003) A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol 31(10):855\u2013864","journal-title":"Exp Hematol"},{"issue":"16","key":"5167_CR22","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","volume":"367","author":"C Anasetti","year":"2012","unstructured":"Anasetti C, Logan B, Lee S, Waller E, Weisdorf D, Wingard J et al (2012) Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367(16):1487\u20131496","journal-title":"N Engl J Med"},{"issue":"15","key":"5167_CR23","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","volume":"123","author":"D Porta","year":"2014","unstructured":"Porta D, Alessandrino E, Bacigalupo A et al (2014) Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 123(15):2333\u20132342","journal-title":"Blood"},{"issue":"17","key":"5167_CR24","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","volume":"129","author":"T Yoshizato","year":"2017","unstructured":"Yoshizato T, Nannya Y, Atsuta Y, Shiozawa Y, Iijima-Yamashita Y, Yoshida K et al (2017) Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129(17):2347\u20132358","journal-title":"Blood"},{"issue":"11","key":"5167_CR25","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1016\/j.bbmt.2020.08.003","volume":"26","author":"A Nazha","year":"2020","unstructured":"Nazha A, Hu ZH, Wang T et al (2020) A personalized prediction model for outcomes after allogeneic hematopoietic cell transplant in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 26(11):2139\u20132146","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5167_CR26","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"26","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K et al (2019) NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 26(3):922\u2013933","journal-title":"Blood Adv"},{"issue":"9","key":"5167_CR27","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41409-019-0469-5","volume":"54","author":"H Itonaga","year":"2019","unstructured":"Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Ohashi K et al (2019) Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 54(9):1471\u20131481","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"5167_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","volume":"379","author":"EJ Duncavage","year":"2018","unstructured":"Duncavage EJ, Jacoby MA, Chang GS et al (2018) Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med 379(11):1028\u20131041","journal-title":"N Engl J Med"},{"issue":"1","key":"5167_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103(1):3\u201310","journal-title":"Int J Hematol"},{"issue":"1","key":"5167_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","volume":"103","author":"J Kanda","year":"2016","unstructured":"Kanda J (2016) Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 103(1):11\u201319","journal-title":"Int J Hematol"},{"issue":"3","key":"5167_CR31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03006932","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al (2007) Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 86(3):269\u2013274","journal-title":"Int J Hematol"},{"issue":"2","key":"5167_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189\u2013199","journal-title":"Br J Haematol"},{"issue":"6","key":"5167_CR33","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079\u20132088","journal-title":"Blood"},{"issue":"4","key":"5167_CR34","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bbmt.2017.11.016","volume":"24","author":"H Itonaga","year":"2018","unstructured":"Itonaga H, Aoki K, Aoki J et al (2018) Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a nationwide retrospective analysis in Japan. Biol Blood Marrow Transplant 24(4):840\u2013848","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5167_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 15(3):367\u2013369","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"5167_CR36","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al (2009) Defining the intensity of conditioning regimens: working definitions. Biol Bone Marrow Transplant 15(12):1628\u20131633","journal-title":"Biol Bone Marrow Transplant"},{"issue":"6","key":"5167_CR37","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825\u2013828","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5167_CR38","first-page":"250","volume":"28","author":"KM Sullivan","year":"1991","unstructured":"Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28(3):250\u2013259","journal-title":"Semin Hematol"},{"issue":"3","key":"5167_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/bjh.13124","volume":"168","author":"K Aoki","year":"2015","unstructured":"Aoki K, Ishikawa T, Ishiyama K, Aoki J, Itonaga H, Fukuda T et al (2015) Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. Br J Haematol 168(3):463\u2013466","journal-title":"Br J Haematol"},{"issue":"11","key":"5167_CR40","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","volume":"122","author":"W Saber","year":"2013","unstructured":"Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD et al (2013) Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood 122(11):1974\u20131982","journal-title":"Blood"},{"issue":"8","key":"5167_CR41","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125(8):1333\u20131338","journal-title":"Blood"},{"issue":"8","key":"5167_CR42","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbmt.2016.04.006","volume":"22","author":"M Solh","year":"2016","unstructured":"Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE et al (2016) Factors predicting graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation: multivariable analysis from a single center. Biol Blood Marrow Transplant 22(8):1403\u20131409","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"5167_CR43","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1200\/JCO.19.00396","volume":"38","author":"R Mehta","year":"2020","unstructured":"Mehta R, Holtan S, Wang T et al (2020) Composite GRFS and CRFS outcomes after adult alternative donor HCT. J Clin Oncol 38(18):2062\u20132076","journal-title":"J Clin Oncol"},{"issue":"9","key":"5167_CR44","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/bloodadvances.2018030171","volume":"3","author":"RS Mehta","year":"2019","unstructured":"Mehta RS, Holtan SG, Wang T et al (2019) GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv 3(9):1441\u20131449","journal-title":"Blood Adv"},{"issue":"19","key":"5167_CR45","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","volume":"17","author":"RB D\u2019Agostino","year":"1998","unstructured":"D\u2019Agostino RB (1998) Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Statist Med 17(19):2265\u20132281","journal-title":"Statist Med"},{"issue":"8","key":"5167_CR46","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"M Sorror","year":"2005","unstructured":"Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912\u20132919","journal-title":"Blood"},{"issue":"3","key":"5167_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5167_CR48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6):695\u2013706","journal-title":"Stat Med"},{"issue":"446","key":"5167_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"5167_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"C Brunstein","year":"2015","unstructured":"Brunstein C, DeFor T, Lazaryan A, Bejanyan N, Arora M, Brunstein C et al (2015) Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 125(8):1333\u20131338","journal-title":"Blood"},{"issue":"11","key":"5167_CR51","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/bloodadvances.2019000077","volume":"3","author":"H Nakasone","year":"2019","unstructured":"Nakasone H, Kawamura K, Yakushijin K et al (2019) BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient. Blood Adv 3(11):1750\u20131760","journal-title":"Blood Adv"},{"issue":"8","key":"5167_CR52","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3324\/haematol.2011.054841","volume":"97","author":"A Bacigalupo","year":"2012","unstructured":"Bacigalupo A, Soci\u00e9 G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M et al (2012) Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica 97(8):1142\u20131148","journal-title":"Haematologica"},{"issue":"7","key":"5167_CR53","first-page":"2303","volume":"92","author":"V Ratanatharathorn","year":"1998","unstructured":"Ratanatharathorn V, Nash R, Przepiorka D, Devine S, Klein J, Weisdorf D et al (1998) Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92(7):2303\u20132314","journal-title":"Blood"},{"issue":"1","key":"5167_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.transproceed.2017.11.035","volume":"50","author":"S Shingaki","year":"2018","unstructured":"Shingaki S, Tsukada N, Ikeda M, Suzuki K (2018) Graft-versus-host disease-free, relapse-free survival after HLA-identical sibling peripheral blood stem cell transplantation with tacrolimus-based graft-versus-host disease prophylaxis in Japanese patients. Transplant Proc 50(1):241\u2013245","journal-title":"Transplant Proc"},{"issue":"2","key":"5167_CR55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1517\/14712598.2014.873027","volume":"14","author":"G Chen","year":"2014","unstructured":"Chen G, Paplham P, McCarthy P (2014) Remestemcel-L for acute graft-versus-host disease therapy. Expert Opin Biol Ther 14(2):261\u2013269","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"5167_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","volume":"103","author":"K Muroi","year":"2016","unstructured":"Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T et al (2016) Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study. Int J Hematol 103(2):243\u2013250","journal-title":"Int J Hematol"},{"issue":"3","key":"5167_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41409-022-01569-x","volume":"57","author":"S Fuji","year":"2022","unstructured":"Fuji S, Hirakawa T, Takano K et al (2022) Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone Marrow Transplant 57(3):479\u2013486","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"5167_CR58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ejh.12214","volume":"92","author":"N Hiramoto","year":"2014","unstructured":"Hiramoto N, Kurosawa S, Tajima K, Okinaka K, Tada K, Kobayashi Y et al (2014) Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. Eur J Haematol 92(2):137\u2013146","journal-title":"Eur J Haematol"},{"issue":"9","key":"5167_CR59","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","volume":"23","author":"F Baron","year":"2005","unstructured":"Baron F, Maris M, Sandmaier B, Storer B, Sorror M, Diaconescu R et al (2005) Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23(9):1993\u20132003","journal-title":"J Clin Oncol"},{"issue":"3","key":"5167_CR60","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"M Horowitz","year":"1990","unstructured":"Horowitz M, Gale R, Sondel P, Goldman J, Kersey J, Kolb H et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 75(3):555\u2013562","journal-title":"Blood."},{"issue":"6","key":"5167_CR61","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood.V73.6.1720.1720","volume":"73","author":"K Sullivan","year":"1989","unstructured":"Sullivan K, Weiden P, Storb R, Witherspoon R, Fefer A, Fisher L et al (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73(6):1720\u20131728","journal-title":"Blood"},{"issue":"4","key":"5167_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1200\/JCO.2007.11.1641","volume":"26","author":"D Valc\u00e1rcel","year":"2008","unstructured":"Valc\u00e1rcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto J et al (2008) Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 26(4):577\u2013584","journal-title":"J Clin Oncol"},{"issue":"5","key":"5167_CR63","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/sj.leu.2403343","volume":"18","author":"Y Kanda","year":"2004","unstructured":"Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y et al (2004) Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 18(5):1013\u20131019","journal-title":"Leukemia"},{"issue":"4","key":"5167_CR64","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/hon.2991","volume":"40","author":"KM Itonaga-H","year":"2022","unstructured":"Itonaga-H KM, Hamamura A et al (2022) Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a propensity score matched analysis. Hematol Oncol 40(4):752\u2013762","journal-title":"Hematol Oncol"},{"issue":"13","key":"5167_CR65","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T Witte","year":"2017","unstructured":"Witte T, Bowen D, Robin M et al (2017) Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 129(13):1753\u20131762","journal-title":"Blood"},{"issue":"30","key":"5167_CR66","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","volume":"34","author":"MG Della Porta","year":"2016","unstructured":"Della Porta MG, Gall\u00ec A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E et al (2016) Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 34(30):3627\u20133637","journal-title":"J Clin Oncol"},{"issue":"25","key":"5167_CR67","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","volume":"32","author":"R Bejar","year":"2014","unstructured":"Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P et al (2014) Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem cell transplantation. J Clin Oncol 32(25):2691\u20132698","journal-title":"J Clin Oncol"},{"issue":"6","key":"5167_CR68","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbmt.2004.02.003","volume":"10","author":"C Bredeson","year":"2004","unstructured":"Bredeson C, Leger C, Couban S, Simpson D, Huebsch L, Walker I et al (2004) An evaluation of the donor experience in the Canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. Biol Blood Marrow Transplant 10(6):405\u2013414","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5167_CR69","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/sj.bmt.1704245","volume":"32","author":"G Favre","year":"2003","unstructured":"Favre G, Beksa\u00e7 M, Bacigalupo A, Ruutu T, Nagler A, Gluckman E et al (2003) Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 32(9):873\u2013880","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5167_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbmt.2008.05.018","volume":"14","author":"J Miller","year":"2008","unstructured":"Miller J, Perry E, Price T, Bolan C, Karanes C, Boyd T et al (2008) Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 14(9):29\u201336","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"5167_CR71","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/bmt.2011.187","volume":"47","author":"J Clausen","year":"2012","unstructured":"Clausen J, Kircher B, Auberger J et al (2012) Bone marrow may be the preferable graft source in recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors. Bone Marrow Transplant 47(6):791\u2013798","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05167-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T07:15:08Z","timestamp":1681370108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05167-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5167"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05167-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}